This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Star Scientific Files First-Quarter Financials For 2013, Reports Continued Growth Of Anatabloc® Sales

GLEN ALLEN, Va. , May 10, 2013 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) today filed with the Securities Exchange Commission its Form 10-Q for the quarter ended March 31, 2013.


The company reported net sales of $2.5 million for the quarter ended March 31, 2013, compared with $1.1 million for the same period in 2012. The increase of 127% was attributable exclusively to increased Anatabloc® sales volume. The company also reported positive gross profits of $1.1 million for first-quarter 2013, compared to a gross profit of $0.4 million for the same period in 2012. The Company has reported increased net sales and positive gross profits in each of the last five quarters.

The net loss for first-quarter 2013 was $(8.2) million compared with a $(5.2) million net loss for the same period in 2012. The increased loss for the first quarter was primarily attributable to increases in sales and marketing costs, legal expenses, and research and development costs. Sales and marketing costs increased as the company expanded promotion of its Anatabloc® dietary supplement product.  As reflected in the 10-Q Report, the Company expects that sales and marketing expenses will trend lower in the near-term as sales and marketing efforts related to Anatabloc® level out in 2013.  Legal fees increased in connection with the previously reported ongoing investigations and class action lawsuits. As discussed in the 10-Q Report, the Company anticipates increased costs in this area in 2013.  

Research and development costs increased in the first quarter as the Company continued to finalize reports on two clinical studies and continued work on its Rosacea clinical trial, which reached full enrollment during the first quarter 2013.  As reported in the 10-Q Report, the Company expects that its R&D costs will trend lower in the near-term as work is finalized on the CRP and Hashimoto's autoimmune thyroiditis clinical studies. 

In February, Anatabloc® was selected as a recipient of the annual GNC Top Vendor Awards. Specifically, Anatabloc® was recognized by GNC as the Wellness Winner in the category of Best Product Innovation for 2012.  More recently, Anatabloc® received registration approval from HFL Sports Science, a leading testing laboratory for banned substances. This qualification permits Star Scientific to use HFL's "Informed-Sport" and "Informed-Choice" trademarks on Registered Products, providing assurance that these products have been tested for substances prohibited in sport.  Also, in January, the Company announced that John Isner, the top-ranked American player on the ATP World Tour, had agreed to act as the Company's second Brand Ambassador for Anatabloc®.  PGA Tour Professional, Fred Couples, continues to serve in his role as the Company's first Anatabloc® Brand Ambassador.

During the first quarter of 2013, the company expanded the Anatabloc® cosmetic products line with the introduction of Anatabloc® Revitalizing Facial Serum.  Both Anatabloc® Facial Creme and Anatabloc® Facial Serum are available on the Company's product website, as well as on GNC's website.

The company announced positive findings during the first quarter of 2013 in connection with an analysis of the initial results for all study subjects who completed the ASAP Human Thyroid health study. The company also reported positive results from a study conducted by researchers at the University of Virginia Medical School investigating the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, ulcerative colitis.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs